Net Income

Kenon Holdings announces a $200M dividend fueled by its OPC Energy unit, whose profits soared in 2025, as it completes its strategic exit from shipping.

UBS sees dozens of its Southeast advisors on Barron's 2026 list, signaling a strategic victory in a key growth market. What does this mean for clients?

Roche has received FDA clearance for two new high-speed diagnostic units designed to alleviate lab staff shortages and dramatically increase testing capacity.

Phase 2 data for HRS/BHB-1893 show rapid efficacy and a simplified regimen, signaling a potential new era for treating hypertrophic cardiomyopathy.

HealthEquity adds Sanford Health CEO Bill Gassen to its board, a strategic move to infuse provider-side expertise into the HSA giant's future.

With a fresh $6M infusion bringing its Series A to $36M, FIZE Medical is accelerating its global push for AI-powered, proactive fluid management in ICUs.

An amended deal with Tasly positions AP Biosciences to license its innovative bispecific cancer therapy to global pharma giants, targeting a lucrative market.

A new drug not only reduces osteoarthritis pain significantly but may also be the first to modify the disease itself, a landmark study in The Lancet reveals.

South Korean AI chip leader Rebellions raises $400M, launching full-stack AI systems to redefine efficient inference and spearhead a global expansion.

Aurinia Pharmaceuticals' deal for Kezar Life Sciences hinges on zetomipzomib, a promising but risky drug poised to tackle a rare autoimmune liver disease.

As Precigen leaders prepare for a key investor chat, all eyes are on the explosive launch of PAPZIMEOS and the company's ambitious path to profitability.

Food-tech firm Beyond Oil is rolling out its oil-purifying tech in a top U.S. supermarket, promising healthier fried food and significant cost savings.

Avory & Co. enters the crowded ETF market with AVRY, an actively managed fund shunning trends for a concentrated portfolio of high-quality stocks.

After a transformative year with key FDA/EU approvals, Pulsenmore's financials get a one-time boost. Can it now conquer the remote prenatal care market?

Husqvarna's new residential mowers boast major comfort and durability upgrades, heating up the spring sales battle against John Deere, Toro, and Cub Cadet.

Clearwater Paper launches Velora™, a new lightweight paperboard balancing cost, sustainability, and domestic supply to capture the everyday packaging market.

Australian medtech firm 4DMedical lands CE Mark for its revolutionary CT:VQ lung imaging, fueling a major European expansion with a fresh AU$83M investment.

A $15M grant fuels a revolutionary therapy for a fatal childhood disease, turning patients' own cells into 'living biofactories' to fight MPS I.

Amid a tough biotech market, the firm extends its cash runway to 2027, accelerating development of its promising rademikibart treatment for respiratory diseases.

Neumora reveals promising data for Alzheimer's and schizophrenia drugs, but a delay in its obesity program highlights the high-stakes world of biotech.